Endogenous opioid-masked latent pain sensitization: Studies from mouse to human

Manuel P. Pereira, Renee R. Donahue, Jørgen B. Dahl, Marianne Werner, Bradley K. Taylor, Mads U. Werner

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Following the resolution of a severe inflammatory injury in rodents, administration of muopioid receptor inverse agonists leads to reinstatement of pain hypersensitivity. The mechanisms underlying this form of latent pain sensitization (LS) likely contribute to the development of chronic pain, but LS has not yet been demonstrated in humans. Using a C57BL/6 mouse model of cutaneous mild heat injury (MHI) we demonstrated a dose-dependent reinstatement of pain sensitization, assessed as primary (P < 0.001) and secondary hyperalgesia (P < 0.001) by naloxone (0.3-10 mg/kg), 168 hrs after the induction of MHI. Forward-translating the dose data to a human MHI model (n = 12) we could show that LS does indeed occur after naloxone 2 mg/kg, 168 hrs after a MHI. Our previous unsuccessful efforts to demonstrate unmasking of LS in humans are thus likely explained by an insufficient naloxone dose (0.021 mg/kg). However, while LS was consistently demonstrated in 21/24 mice, LS was only seen in 4/12 subjects. This difference is likely due to selection bias since the C57BL/6 mouse strain exhibits markedly enhanced pain sensitivity in assays of acute thermal nociception. Future exploratory studies in humans should prioritize inclusion of "high-sensitizers" prone to develop LS and use post-surgical models to elucidate markers of vulnerability to chronic postsurgical pain.

Original languageEnglish (US)
Article numbere0134441
JournalPloS one
Volume10
Issue number8
DOIs
StatePublished - Aug 25 2015

Bibliographical note

Publisher Copyright:
© 2015 Pereira et al.

Fingerprint Dive into the research topics of 'Endogenous opioid-masked latent pain sensitization: Studies from mouse to human'. Together they form a unique fingerprint.

Cite this